Julia Lopes Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Lopes Garcia has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ana Karine Vieira
Universidade Federal de Minas Gerais – Hospital das Clínicas – Belo Horizonte (MG), Brazil|Grupo Santa Casa de Belo Horizonte – Belo Horizonte (MG), Brazil
2 shared publications - Roseane Vasconcelos Gouveia
Hospital Samaritano de São Paulo – São Paulo (SP), Brazil|Universidade Federal de São Paulo – Escola Paulista de Medicina – São Paulo (SP), Brazil|Grupo de Apoio ao Adolescente e à Criança com Câncer – São Paulo (SP), Brazil
2 shared publications - Adriana Aparecida Siviero-Miachon
Universidade Federal de São Paulo, São Paulo SP, Brazil
1 shared publication - Alexandre de Albuquerque Antunes
Universidade Federal de Minas Gerais – Belo Horizonte (MG), Brazil
1 shared publication - Antonio Vaz de Macedo
Hospital da Polícia Militar – Belo Horizonte (MG), Brazil
1 shared publication - Augusto Oliveira Silva
Hospital Pequeno Príncipe – Curitiba (PR), Brazil
1 shared publication
Latest Publications
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic stem cell transplantation in children with thalassemia: Brazilian Society of Bone Marrow Transplantation Consensus
Allogeneic hematopoietic cell transplantation (HCT) represents a critical therapeutic option for patients with transfusiondependent thalassemia (TDT), with thalassemia-free survival rates exceeding 90% in cases involving HLA-matched sibling donors. Due to the limited availability of matched donors, alternative sources such as HLA-matched unrelated donors, haploidentical donors, and umbilical cord blood have broadened HCT eligibility. Despite its potential for cure, HCT involves risks like graft-versus-host disease, graft rejection, and transplant-related mortality. Recent improvements in conditioning regimens have enhanced patient outcomes and quality of life. Factors affecting HCT success in TDT include recipient age, disease complications, effective chelation therapy, Pesaro score, and donor compatibility. This article aimed to update the Brazilian consensus established by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, incorporating the latest advances in treating and managing TDT patients undergoing transplantation.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic stem cell transplantation in children with thalassemia: Brazilian Society of Bone Marrow Transplantation Consensus
Allogeneic hematopoietic cell transplantation (HCT) represents a critical therapeutic option for patients with transfusiondependent thalassemia (TDT), with thalassemia-free survival rates exceeding 90% in cases involving HLA-matched sibling donors. Due to the limited availability of matched donors, alternative sources such as HLA-matched unrelated donors, haploidentical donors, and umbilical cord blood have broadened HCT eligibility. Despite its potential for cure, HCT involves risks like graft-versus-host disease, graft rejection, and transplant-related mortality. Recent improvements in conditioning regimens have enhanced patient outcomes and quality of life. Factors affecting HCT success in TDT include recipient age, disease complications, effective chelation therapy, Pesaro score, and donor compatibility. This article aimed to update the Brazilian consensus established by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, incorporating the latest advances in treating and managing TDT patients undergoing transplantation.
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Long-term follow-up after pediatric hematopoietic stem cell transplantation
This article, part of the Pediatric Group consensus of the Brazilian Society of Bone Marrow Transplantation, addresses lifelong follow-up in pediatric hematopoietic stem cell transplant survivors. With the growing number of long-term survivors, specialized monitoring is essential, especially for high-risk groups such as infants, recipients of total body irradiation, and those with inherited bone marrow failure syndromes. The consensus outlines surveillance strategies for detecting and managing late complications, including chronic graft-versus-host disease and secondary effects. Multidisciplinary recommendations aim to optimize early intervention and quality of life, establishing a standardized follow-up framework for pediatric transplant care in Brazil.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessLong-term follow-up after pediatric hematopoietic stem cell transplantation
This article, part of the Pediatric Group consensus of the Brazilian Society of Bone Marrow Transplantation, addresses lifelong follow-up in pediatric hematopoietic stem cell transplant survivors. With the growing number of long-term survivors, specialized monitoring is essential, especially for high-risk groups such as infants, recipients of total body irradiation, and those with inherited bone marrow failure syndromes. The consensus outlines surveillance strategies for detecting and managing late complications, including chronic graft-versus-host disease and secondary effects. Multidisciplinary recommendations aim to optimize early intervention and quality of life, establishing a standardized follow-up framework for pediatric transplant care in Brazil.
- Open Access
- 12 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Palliative care
Palliative care is an essential component of comprehensive care for children and adolescents undergoing hematopoietic stem cell transplantation (HSCT), yet it remains inconsistently integrated into clinical practice. This consensus chapter establishes principles and recommendations for the systematic incorporation of pediatric palliative care within HSCT programs. It emphasizes early integration, shared decision-making, and alignment of care with patient and family values throughout the transplant trajectory, regardless of prognosis. Key domains addressed include eligibility criteria, functional and prognostic assessment, communication strategies, ethical and legal considerations, and multidisciplinary collaboration. The chapter also reviews existing institutional models of palliative care integration and highlights adaptable frameworks suited to diverse resource settings. By standardizing approaches and clarifying roles, this consensus seeks to reduce variability in care, improve quality of life, and promote ethically sound, patient-centered decision-making. Integrating palliative care as a core element of pediatric HSCT policy is critical to improving both quality-of-life and end-of-life outcomes for patients and families.
- 12 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessPalliative care
Palliative care is an essential component of comprehensive care for children and adolescents undergoing hematopoietic stem cell transplantation (HSCT), yet it remains inconsistently integrated into clinical practice. This consensus chapter establishes principles and recommendations for the systematic incorporation of pediatric palliative care within HSCT programs. It emphasizes early integration, shared decision-making, and alignment of care with patient and family values throughout the transplant trajectory, regardless of prognosis. Key domains addressed include eligibility criteria, functional and prognostic assessment, communication strategies, ethical and legal considerations, and multidisciplinary collaboration. The chapter also reviews existing institutional models of palliative care integration and highlights adaptable frameworks suited to diverse resource settings. By standardizing approaches and clarifying roles, this consensus seeks to reduce variability in care, improve quality of life, and promote ethically sound, patient-centered decision-making. Integrating palliative care as a core element of pediatric HSCT policy is critical to improving both quality-of-life and end-of-life outcomes for patients and families.